GSK (GSK.L) announced its experimental hepatitis B treatment bepirovirsen met primary endpoints in two phase III studies, advancing regulatory filing plans. The positive results for the potential first-in-class therapy could address a significant unmet medical need for chronic hepatitis B patients seeking functional cures.
Key Takeaways
- Bepirovirsen achieved statistically significant functional cure rates in trials
- GSK plans regulatory filings based on B-Well study results
- Drug represents potential first-in-class chronic hepatitis B treatment
Market reaction & context
The British pharmaceutical giant said bepirovirsen demonstrated statistically significant and clinically meaningful functional cure rates in the B-Well 1 and B-Well 2 phase III trials 1. GSK will use these results to support planned regulatory applications for the antisense oligonucleotide therapy.
The hepatitis B treatment market represents a substantial opportunity, with approximately 296 million people worldwide living with chronic hepatitis B infection. Current treatments typically require lifelong therapy, making functional cure approaches highly sought after by patients and physicians.
Detailed analysis
Bepirovirsen works by targeting hepatitis B virus RNA through an antisense mechanism, potentially offering a novel approach to achieving functional cures. The drug was developed in partnership with Ionis Pharmaceuticals (IONS.O), which announced the positive topline results alongside GSK 4.
The B-Well studies evaluated bepirovirsen’s ability to achieve sustained loss of hepatitis B surface antigen, a key marker for functional cure in chronic hepatitis B patients. Functional cure means patients maintain undetectable viral levels without ongoing antiviral therapy.
Regulatory pathway
GSK indicated it will use the phase III data to support regulatory submissions, though the company has not specified exact timing for filing applications. The positive results represent a significant milestone for the program, which has been closely watched by the hepatitis B treatment community.
Industry analysts view functional cure approaches as potentially transformative for chronic hepatitis B management, given the limitations of current standard-of-care treatments that require indefinite dosing.
Partnership implications
The successful trial outcomes also benefit Ionis Pharmaceuticals, GSK’s development partner for bepirovirsen. Ionis maintains certain milestone and royalty rights to the program under their collaboration agreement.
Both companies emphasized the clinical significance of achieving functional cure rates in a patient population with limited therapeutic options beyond suppressive antiviral therapy.
Conclusion
GSK’s positive bepirovirsen results mark a potential breakthrough in chronic hepatitis B treatment, positioning the company to advance regulatory filings for what could become a first-in-class functional cure therapy. The success strengthens GSK’s infectious disease pipeline while addressing a significant global health need.
Not investment advice. For informational purposes only.
References
1“GSK’s chronic hepatitis B therapy shows promise in key studies”. Reuters. Retrieved January 7, 2026.
2“GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen”. GSK. Retrieved January 7, 2026.
3“GSK’s chronic hepatitis B treatment meets main goal in key studies”. Yahoo Finance. Retrieved January 7, 2026.
4“Ionis partner GSK announces positive topline results from B-Well 1”. Ionis Pharmaceuticals. Retrieved January 7, 2026.
5“GSK’s chronic hepatitis B treatment meets main goal in key studies”. WMBD Radio. Retrieved January 7, 2026.
6“GSK’s hepatitis B drug shows positive results in phase 3 trials”. Investing.com. Retrieved January 7, 2026.
7“GSK’s chronic hepatitis B therapy shows promise in key studies”. MarketScreener. Retrieved January 7, 2026.
8“GSK reports breakthrough trial results for hepatitis B drug”. ProActive Investors. Retrieved January 7, 2026.